Evidence map›Paper›PMID 41013700›Full record

ArticleJournal of nanobiotechnology2025

Biomimetic Cu

Sijia Lin, Haiyan Xing, Yu Zeng, Elvira Galimova, Alexandr Chernov, Guodong Liu, Peng Xue

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Multifunctional CuFrontiers in chemistry · 2026
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sijia Lin *Department of Neurosurgery, The Second Affiliated Hospital of Chongqing, Medical University, Chongqing, 400016, China.
Haiyan Xing *School of Materials and Energy, Southwest University, Chongqing, 400715, China.
Yu Zeng *Department of Neurosurgery, The Second Affiliated Hospital of Chongqing, Medical University, Chongqing, 400016, China.
Elvira GalimovaSechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Saint-Petersburg, 194223, Russia.
Alexandr ChernovFederal State Budgetary Educational Institution of Higher Education, Saint Petersburg State Pediatric Medical University, Saint-Petersburg, 194100, Russia.
Guodong LiuDepartment of Neurosurgery, The Second Affiliated Hospital of Chongqing, Medical University, Chongqing, 400016, China. 304678@hospital.cqmu.edu.cn.
Peng XueSchool of Materials and Energy, Southwest University, Chongqing, 400715, China. xuepeng@swu.edu.cn.

Funding

Key Research and Development Project of Sichuan Provincial Science and Technology Plan 2024YFFK0249Open Research Project from Anhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment KFKT202405Scientific and Technological Research Program of Chongqing Municipal Education Commission KJQN202100467Scientific and Technological Research Program of Chongqing Municipal Education Commission KJQN202400202
6 · The paper itself

Abstract

Glioblastoma (GBM) is an aggressive and highly heterogeneous brain tumor that continues to pose a significant clinical challenge. Current therapeutic strategies, including surgical resection, radiotherapy, and chemotherapy, are hindered by the tumor's invasive behavior, resistance to treatment, and the difficulty of selectively targeting tumor cells. Emerging modalities, such as immunotherapy and photodynamic therapy, hold considerable promise; however, their efficacy in treating GBM is limited by critical barriers, including poor penetration of the blood-brain barrier (BBB), tumor heterogeneity, and insufficient accumulation of therapeutic agents at the tumor site. In this study, innovative biomimetic copper selenide nanoparticles (CS@CM) are developed for targeted photothermal therapy of GBM. These nanoparticles are functionalized with glioma cell membranes (CM), and this biomimetic design leverages the homing capability of the membranes to achieve efficient BBB penetration and enhanced targeting of GBM tissues. CS@CM act as potent photothermal agents upon light activation, which can amplify reactive oxygen species-induced oxidative stress to damage glioma cells. Such combination therapy effectively triggers immunogenic cell death to achieve splendid antitumor efficacy, offering a promising therapeutic strategy for GBM. Collectively, this approach addresses the limitations of conventional treatments, paving the way for improved clinical outcomes in managing this formidable malignancy.

Indexed as

Biomimetic MaterialsBlood-Brain BarrierBrain NeoplasmsCopperGlioblastomaNanoparticlesAnimalsCell Line, TumorHumansImmunogenic Cell DeathMiceReactive Oxygen SpeciesSeleniumCopperReactive Oxygen SpeciesSeleniumBlood-brain barrier penetrationGlioblastoma therapyImmunogenetic cell deathOxidative damage

Identifiers

PMID41013700
PMCPMC12465653

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.